Suppliers / Phyton Biotech

Phyton Biotech

Germany Updated 9 July 2026

Phyton Biotech is a contract manufacturer based in Germany. It holds 2 active US drug master files and 3 valid CEPs across a filed portfolio of 2 molecules. Its GMP standing is certified by ZLG (DE) and US FDA. Its most recent recorded inspection, by US FDA, closed on 19 October 2024 as VAI.

2
active US DMFs
3
valid CEPs
4
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 19 October 2024 VAI US FDA
  • 29 March 2023 VAI US FDA
  • 20 February 2020 VAI US FDA
  • 28 August 2019 NAI US FDA
  • 15 September 2017 NAI US FDA
  • 15 July 2016 VAI US FDA
  • 24 October 2014 VAI US FDA
  • 27 September 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Delta, Canada Not on file
Canada, Canada 3006110823
Ahrensburg, Germany Not on file
Germany, Germany 3002807883

What they file, and where

Molecule Regulators Docs
Docetaxel EDQM, SFDA (Saudi Arabia), US FDA 4
Paclitaxel EDQM, SFDA (Saudi Arabia), US FDA 4

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
ZLG (DE) None 4
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Phyton Biotech comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 19 October 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates